Louie Pasculli, Assistant Editor for NeurologyLive®, has been with the team since October 2025. Follow him on X @Louie_Pasculli or email him at [email protected]
The director of the Stony Broke MS Comprehensive Care Center reviewed late-breaking subgroup data evaluating high-efficacy therapy in patients with highly active relapsing multiple sclerosis and discussed the evolving role of early intervention. [WATCH TIME: 5 minutes]
A literature review suggests ferritin may serve as a “dual-edged” biomarker in multiple sclerosis, with elevated levels associated with disease progression and low levels linked to impaired remyelination.
Preliminary phase 1a findings suggest the investigational tau aggregation inhibitor OLX-07010 demonstrated favorable safety and pharmacokinetic profiles in healthy volunteers, supporting continued development in Alzheimer disease.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is mitochondrial dysfunction in neurodegeneration!
Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute discussed how structured cardiovascular rehabilitation may improve recovery outcomes, reduce mortality, and influence future Medicare coverage for poststroke care.
Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed emerging evidence supporting structured cardiovascular rehabilitation after stroke and ongoing efforts to expand access through potential Medicare policy changes.
The FDA's acceptance and priority review of levacetylleucine for ataxia-telangiectasia positions the therapy to potentially become the first approved treatment for the rare neurodegenerative disorder.
From exercise and lifestyle medicine to neuromodulation and vagus nerve stimulation, Andrew Abdou, DO, discusses emerging approaches that may help stroke patients continue recovery beyond traditional timelines.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is glymphatic system for Parkinson!
The professor of cognitive neuroscience and imaging at the University of Western Ontario, Canada, detailed new research using the Creyos platform and machine learning to develop a rapid, scalable cognitive screener designed to identify early signs of cognitive decline and dementia risk.
Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.
A prospective postapproval study showed that responsive neurostimulation with the RNS System was associated with sustained seizure reductions and a favorable interim safety profile over 3 years in adults with drug-resistant focal epilepsy.
A phase 2 trial found that the oral complement factor D inhibitor vemircopan did not demonstrate efficacy over placebo in adults with acetylcholine receptor antibody–positive generalized myasthenia gravis, leading to early termination of the study.
Kinan Muhammed, MD, PhD, consultant neurologist and co-founder and Chief Medical Officer for Kneu Health, discussed how smartphone-based remote monitoring tools may help clinicians track motor and cognitive changes in Parkinson disease and dementia more continuously.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Stroke Awareness Month!
BIOX-101 showed early signals of reduced edema growth and improved functional outcomes in a phase 2a intracerebral hemorrhage trial, with a favorable safety profile, supporting advancement into a planned adaptive phase 2b/3 study.
The FDA has expanded the use of efgartigimod alfa-fcab and Hytrulo to include adults with AChR-Ab seronegative generalized myasthenia gravis, marking the first approved FcRn-targeted therapy for this patient population.
Neurava secured a $4M NIH grant to develop and validate an AI-driven wearable platform for SUDEP risk prediction and real-time monitoring, aiming to improve clinical decision-making and early intervention in epilepsy care.
Clene plans to pursue accelerated FDA approval for CNM-Au8 in ALS based primarily on neurofilament light biomarker data and phase 2 studies, with a confirmatory phase 3 trial expected to follow.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is dyskinesia treatment options!
A recently published review reinforces ketogenic diet therapies as a clinically relevant option for epilepsy, particularly in pediatric and metabolic populations, while underscoring the need for more rigorous evidence to guide their optimal use.
GMRx2 reduced recurrent stroke risk by 39% in patients with prior intracerebral hemorrhage in the phase 3 TRIDENT trial, supporting single-pill intensive blood pressure control as a promising secondary prevention strategy.
The founder and president of the Indian Federation of Neurorehabilitation highlighted emerging technologies and evolving therapeutic strategies shaping the future of neurorehabilitation. [WATCH TIME: 5 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the MOGAD pipeline!
FDA issues complete response letter for GTx-104 in aneurysmal subarachnoid hemorrhage, citing manufacturing and nonclinical concerns despite positive phase 3 efficacy and safety data.
In the phase 3 NIMBLE trial, Cemdisiran met primary and secondary endpoints, demonstrating rapid and sustained improvements in MG-ADL and QMG scores with once-every-12-week dosing in AChR-positive generalized myasthenia gravis.
A medical student at at Santa Casa de São Paulo School of Medical Sciences discussed the findings from a systematic review suggest potential biomarker-level benefits of estradiol-based hormone therapy in Alzheimer disease, but cautions that heterogeneous data limit firm conclusions. [WATCH TIME: 3 minutes]
In the global phase 3 PREVAIL trial, gefurulimab met primary and secondary endpoints in adults with acetylcholine receptor antibody–positive generalized myasthenia gravis, potentially offering a more convenient alternative to intravenous therapies.
In a 58-week open-label extension, most patients with Parkinson disease treated with tavapadon avoided starting levodopa or required no dose increases, suggesting a potential levodopa-sparing effect.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric strokes!
